PRME.NASDAQPrime Medicine, INC
DEF: Prime Medicine Sets 2026 Annual Meeting Date
Sentiment:
Proxy Statement
Prime Medicine, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 5, 2026, to elect directors and ratify auditor appointment.
Summary
- Prime Medicine, Inc. is holding its 2026 Annual Meeting of Stockholders on June 5, 2026, at 2:00 p.m. Eastern Time, via a virtual webcast.
- The meeting's agenda includes the election of Michael Kelly and David Schenkein, M.D. as Class I Directors for three-year terms, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The record date for determining stockholders entitled to notice and to vote is April 9, 2026.
- Proxy materials will be made available online, with a Notice of Internet Availability of Proxy Materials being mailed on or about April 23, 2026.
- Stockholders can vote via the internet, telephone, or mail, with deadlines generally set for June 4, 2026.
- The company is an emerging growth company and has utilized reduced disclosure requirements.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns procedural matters for the annual shareholder meeting and does not contain new financial performance data or strategic updates.
Positives
- The company is holding its annual meeting to ensure continued governance and oversight.
- Nomination of experienced directors Michael Kelly and David Schenkein, M.D. for re-election.
- Ratification of PricewaterhouseCoopers LLP as auditor, indicating continued reliance on established audit services.
- The virtual meeting format allows for broader stockholder participation.
- The company is utilizing the notice and access approach for proxy materials, which is cost-effective and environmentally friendly.
Risks
- The filing does not contain specific financial performance data or forward-looking statements that would indicate risks related to business operations or financial health.
- The primary risks discussed are related to the election of directors and the ratification of the auditor, which are standard procedural matters.
Future Outlook
The filing is a proxy statement for an upcoming annual meeting and does not contain specific forward-looking financial guidance or operational outlooks. The focus is on procedural matters for the meeting.
Management Comments
- "We are pleased to notify you that we will hold the 2026 annual meeting of our stockholders, or the Annual Meeting, on June 5, 2026, at 2:00 p.m., Eastern Time, in a virtual meeting format, which will be conducted via live webcast."
- "Whether you plan to attend the Annual Meeting or not, it is important that your shares be represented. You may vote over the Internet, via telephone or by mail."
- "Thank you for your continued support of Prime Medicine, Inc."
Industry Context
StockSavvy.ai notes that this filing is typical for a publicly traded biotechnology company preparing for its annual shareholder meeting. The focus on director elections and auditor ratification reflects standard corporate governance practices. The virtual meeting format aligns with current trends in corporate communications.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class I Director | Michael Kelly | June 5, 2026 | Nominated for re-election | |
| Class I Director | David Schenkein, M.D. | June 5, 2026 | Nominated for re-election | |
| Chief Financial Officer | Svetlana N. Makhni | April 2026 | Hired as CFO | |
| Chief Executive Officer | Keith Gottesdiener, M.D. | Allan Reine, M.D. | May 2025 | Transition from CFO to CEO |
| Former Chief Executive Officer | Keith Gottesdiener, M.D. | May 18, 2025 | Separation from the company | |
| Former Chief Scientific Officer | Jeremy Duffield, M.D., Ph.D., FRCP | July 15, 2025 | Separation from the company |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Leadership Structure | Separation of CEO and Executive Chair roles, with Jeffrey D. Marrazzo serving as Executive Chair and Allan Reine, M.D. as CEO. | May 2025 | Believed to allow CEO to focus on operations while Executive Chair provides oversight and facilitates communication. |
| Director Nomination Process | Nominating and corporate governance committee considers various factors including professional accomplishment, board culture, business knowledge, and relevant experience. | Ongoing | Aims to ensure a well-qualified and diverse board. |
| Director Independence | Board reviewed director independence in February 2026, determining all directors except Allan Reine, M.D. and Jeffrey D. Marrazzo are independent. | February 2026 | Complies with Nasdaq listing rules and SEC regulations. |
| Board Committees | Audit, Compensation, and Nominating and Corporate Governance committees operate under adopted charters. | Ongoing | Ensures specialized oversight in key areas of corporate governance. |
| Code of Business Conduct and Ethics | Adopted Code applies to all employees, officers, directors, agents, and representatives. | Ongoing | Promotes ethical conduct and compliance with laws and regulations. |
| Insider Trading Policy | Prohibits short sales and derivative transactions, but permits trading plans under Rule 10b5-1. | Ongoing | Aims to prevent insider trading and promote fair markets. |
| Compensation Recovery Policy | Allows recovery of incentive-based compensation in case of financial restatements due to material noncompliance. | October 2, 2023 | Aligns executive compensation with accurate financial reporting. |
| Equity Award Grant Policy | Sets forth process and timing for granting equity awards, with Board/Committee approval or CEO delegation. | Ongoing | Ensures consistent and non-manipulative equity award practices. |
| Related Party Transactions Policy | Requires review and approval of related party transactions by the audit committee. | Adopted | Ensures fairness and transparency in transactions with related parties. |
Related Party Transactions
- GV, ARCH Venture Partners, and Newpath Partners, L.P. (affiliated with directors David Schenkein, Robert Nelsen, and Thomas Cahill, respectively) purchased shares in follow-on public offerings in February 2024 and August 2025.
- Bristol-Myers Squibb (BMS) entered into a research collaboration and license agreement and a stock purchase agreement in September 2024, making BMS a beneficial owner of over 5% of the company's stock.
- Jeffrey D. Marrazzo, Executive Chair and director, had an advisory services agreement from February 2024 to February 2025, receiving an annual fee and stock options.
- Jeffrey D. Marrazzo also has an Executive Chair agreement from May 2025, with an annual fee and stock options.
- The company entered into a settlement agreement in January 2024 with Myeloid, resolving arbitration proceedings for a payment of $13.5 million.
Stakeholder Impact
- Shareholders: The election of directors and ratification of the auditor are key governance matters impacting shareholder rights and oversight.
- Management and Employees: Executive compensation details and equity award policies are outlined, influencing employee motivation and retention.
- Auditors: The ratification of PricewaterhouseCoopers LLP confirms their continued role in auditing the company's financial statements.
Next Steps
- Stockholders to vote on the election of directors and ratification of the independent registered public accounting firm.
- The company will hold its 2026 Annual Meeting of Stockholders on June 5, 2026.
- Proxy materials will be made available to stockholders on or about April 23, 2026.
Key Dates
| Date | Description |
|---|---|
| 2022-10-01 | Initial public offering (IPO) completion date (mentioned in context of emerging growth company status). |
| 2023-09-15 | Date of adoption of the compensation recovery policy. |
| 2023-10-02 | Effective date of the compensation recovery policy. |
| 2024-01-01 | Start of the period for which related party transactions are reviewed. |
| 2024-02-29 | Date of the advisory services agreement with Jeffrey D. Marrazzo. |
| 2024-09-01 | Date of the research collaboration and license agreement with Juno (BMS). |
| 2024-10-04 | Date of Schedule 13G filing by BMS. |
| 2024-11-12 | Date of Schedule 13G/A filing by GV. |
| 2024-12-13 | Date of filing of registration statement on Form S-3 for BMS Shares resale. |
| 2024-12-20 | Effective date of registration statement on Form S-3 for BMS Shares resale. |
| 2025-01-01 | Start of fiscal year for which financial statements are discussed. |
| 2025-02-01 | Date of expiration of the advisory services agreement with Jeffrey D. Marrazzo. |
| 2025-03-31 | Date related to the Duffield Consulting Agreement termination and option exercise period. |
| 2025-04-23 | Date of the proxy statement. |
| 2025-05-16 | Date the Board approved the second amended and restated non-employee director compensation policy. |
| 2025-05-19 | Effective date of the Amended and Restated Employment Agreement for Allan Reine, M.D. as CEO. |
| 2025-05-19 | Date of Executive Chair Agreement with Jeffrey D. Marrazzo. |
| 2025-05-18 | Date of Keith Gottesdiener, M.D.'s separation from the company. |
| 2025-07-15 | Date of Jeremy Duffield, M.D., Ph.D., FRCP's separation from the company. |
| 2025-08-01 | Date of repricing of certain stock options. |
| 2025-12-31 | End of fiscal year for which financial statements are discussed. |
| 2026-01-01 | Date of automatic increase in shares available under the 2022 Plan. |
| 2026-03-31 | Date related to the Duffield Consulting Agreement termination and option exercise period. |
| 2026-04-09 | Record date for the 2026 Annual Meeting of Stockholders. |
| 2026-04-23 | Date on which the Notice of Internet Availability of Proxy Materials will commence being sent. |
| 2026-06-04 | Deadline for voting by internet or telephone for the Annual Meeting. |
| 2026-06-05 | Date of the 2026 Annual Meeting of Stockholders. |
| 2026-12-24 | Deadline for stockholder proposals to be considered for inclusion in the 2027 proxy materials. |
| 2027-02-05 | Earliest date for stockholder proposals or director nominations to be brought before the 2027 Annual Meeting. |
| 2027-03-07 | Latest date for stockholder proposals or director nominations to be brought before the 2027 Annual Meeting. |
| 2027-09-30 | Date until which BMS has agreed not to sell or transfer certain shares. |
Recommendation
holdThis filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic updates, or material non-public information that would warrant a buy or sell recommendation. It focuses on governance matters and director elections.
Keywords
Prime Medicine, Proxy Statement, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Virtual Meeting, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.